William Blair Has Negative Outlook for Hologic Q4 Earnings

Key Points

• William Blair has lowered its Q4 2025 earnings estimate for Hologic to $1.08 per share, down from a previous estimate of $1.10.
• Raymond James Financial maintains an "outperform" rating but has reduced their target price for Hologic's shares from $90.00 to $71.00.
• Hologic's stock has an average rating of "Hold" from analysts, with an average price target of $76.42 and significant institutional ownership, accounting for 94.73% of shares.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Stock analysts at William Blair reduced their Q4 2025 earnings per share (EPS) estimates for Hologic in a research report issued on Thursday, July 31st. William Blair analyst A. Brackmann now forecasts that the medical equipment provider will earn $1.08 per share for the quarter, down from their previous forecast of $1.10. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic's Q1 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.11 EPS, Q4 2026 earnings at $1.15 EPS and FY2026 earnings at $4.47 EPS.

Several other equities analysts have also commented on HOLX. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group raised their price target on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the stock from $72.00 to $87.00 in a report on Wednesday. Finally, Morgan Stanley boosted their target price on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $77.83.

Hologic Price Performance

HOLX traded up $0.80 during trading on Monday, reaching $67.69. The stock had a trading volume of 539,302 shares, compared to its average volume of 2,837,641. The stock has a market cap of $15.06 billion, a PE ratio of 28.09, a PEG ratio of 2.46 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic has a one year low of $51.90 and a one year high of $84.67. The business has a 50-day moving average of $64.87 and a 200-day moving average of $62.77.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $1.06 earnings per share. The company's revenue for the quarter was up 1.2% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA grew its position in shares of Hologic by 56.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 44,291 shares of the medical equipment provider's stock worth $3,193,000 after buying an additional 16,012 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new position in shares of Hologic in the 4th quarter valued at about $6,090,000. Federated Hermes Inc. raised its stake in Hologic by 35.8% during the fourth quarter. Federated Hermes Inc. now owns 7,720 shares of the medical equipment provider's stock worth $557,000 after acquiring an additional 2,036 shares during the period. Prospector Partners LLC boosted its stake in Hologic by 20.9% in the fourth quarter. Prospector Partners LLC now owns 160,491 shares of the medical equipment provider's stock valued at $11,570,000 after acquiring an additional 27,786 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Hologic by 45.1% during the 4th quarter. Bank of Montreal Can now owns 714,377 shares of the medical equipment provider's stock worth $51,499,000 after purchasing an additional 222,167 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.